Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 58, Issue 7, 2009, Pages 989-994

  Pop Busui, Rodica ^a   Oral, Elif ^a   Raffel, David ^b   Byun, Jaeman ^a   Bajirovic, Valida ^a   Vivekanandan Giri, Anuradha ^a   Kellogg, Aaron ^a   Pennathur, Subramaniam ^a   Stevens, Martin J ^c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ADIPONECTIN; AMMONIA; C REACTIVE PROTEIN; GLIBENCLAMIDE; GLIPIZIDE; GLYCOSYLATED HEMOGLOBIN; INSULIN; LIPID; METFORMIN; REACTIVE NITROGEN SPECIES; ROSIGLITAZONE; SULFONYLUREA; VON WILLEBRAND FACTOR;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; COLD PRESSOR TEST; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFECT; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE PERFUSION; HUMAN; HYPOGLYCEMIA; INFLAMMATION; ISOTOPE DILUTION ASSAY; LIPID BLOOD LEVEL; MALE; MASS FRAGMENTOGRAPHY; NITROSATIVE STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; THORAX PAIN;

ADIPONECTIN; ADULT; BLOOD GLUCOSE; C-REACTIVE PROTEIN; COHORT STUDIES; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; MALE; MIDDLE AGED; MYOCARDIUM; POSITRON-EMISSION TOMOGRAPHY; REACTIVE NITROGEN SPECIES; THIAZOLIDINEDIONES; TYROSINE; VON WILLEBRAND FACTOR;

EID: 66349092426     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.02.020     Document Type: Article

References (42)

1. Stamler J., Vaccaro O., Neaton J.D., et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
2. Reaven G.M., and Laws A. Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease. Diabetologia 37 (1994) 948-952
3. Haffner S.M., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
4. Williams S.B., Cusco J.A., Roddy M.A., et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 27 (1996) 567-574
5. Quinones M.J., Hernandez-Pampaloni M., Schelbert H., et al. Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med 140 (2004) 700-708
6. Nitenberg A., Valensi P., Sachs R., et al. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 42 (1993) 1017-1025
7. Yokoyama I., Ohtake T., Momomura S., et al. Hyperglycemia rather than insulin resistance is related to reduced coronary flow reserve in NIDDM. Diabetes 47 (1998) 119-124
8. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304 (1981) 801-807
9. Haffner S.M., D'Agostino Jr. R., Mykkanen L., et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 22 (1999) 562-568
10. Bruce C.R., Carey A.L., Hawley J.A., et al. Intramuscular heat shock protein 72 and heme oxygenase-1 mRNA are reduced in patients with type 2 diabetes: evidence that insulin resistance is associated with a disturbed antioxidant defense mechanism. Diabetes 52 (2003) 2338-2345
11. Baynes J.W., and Thorpe S.R. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 28 (2000) 1708-1716
12. Pennathur S., and Heinecke J.W. Mechanisms for oxidative stress in diabetic cardiovascular disease. Antioxid Redox Signal 9 (2007) 955-969
13. Shishehbor M.H., Aviles R.J., Brennan M.L., Fu X., Goormastic M., Pearce G.L., et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 289 (2003) 1675-1680
14. Garcia Soriano F., Virag L., Jagtap P., et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 7 (2001) 108-113
15. Mabley J.G., and Soriano F.G. Role of nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic vascular dysfunction. Curr Vasc Pharmacol 3 (2005) 247-252
16. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
17. Meier J.J., Gallwitz B., Schmidt W.E., et al. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?. Heart 90 (2004) 9-12
18. Standards of medical care in diabetes-2006. Diabetes Care 29 Suppl 1 (2006) S4-S42
19. Pop-Busui R., Kirkwood I., Schmid H., et al. Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol 44 (2004) 2368-2374
20. Stevens M.J., Dayanikli F., Raffel D.M., et al. Scintigraphic assessment of regionalized defects in myocardial sympathetic innervation and blood flow regulation in diabetic patients with autonomic neuropathy. J Am Coll Cardiol 31 (1998) 1575-1584
21. Pennathur S., Bergt C., Shao B., et al. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem 279 (2004) 42977-42983
22. Szabo G., and Bahrle S. Role of nitrosative stress and poly(ADP-ribose) polymerase activation in myocardial reperfusion injury. Curr Vasc Pharmacol 3 (2005) 215-220
23. Garratt K.N., Brady P.A., Hassinger N.L., et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 33 (1999) 119-124
24. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 357 (2007) 28-38
25. Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
26. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443
27. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
28. McMahon G.T., Plutzky J., Daher E., et al. Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes. Diabetes Care 28 (2005) 1145-1150
29. Sekiya M., Suzuki J., Watanabe K., et al. Beneficial effect of troglitazone, an insulin-sensitizing antidiabetic agent, on coronary circulation in patients with non-insulin-dependent diabetes mellitus. Jpn Circ J 65 (2001) 487-490
30. Farouque H.M., Worthley S.G., and Meredith I.T. Effect of ATP-sensitive potassium channel inhibition on coronary metabolic vasodilation in humans. Arterioscler Thromb Vasc Biol 24 (2004) 905-910
31. Imamura Y., Tomoike H., Narishige T., et al. Glibenclamide decreases basal coronary blood flow in anesthetized dogs. Am J Physiol 263 (1992) H399-H404
32. Duncker D.J., Van Zon N.S., Altman J.D., et al. Role of K+ATP channels in coronary vasodilation during exercise. Circulation 88 (1993) 1245-1253
33. Loubani M., Fowler A., Standen N.B., et al. The effect of gliclazide and glibenclamide on preconditioning of the human myocardium. Eur J Pharmacol 515 (2005) 142-149
34. Molavi B., Chen J., and Mehta J.L. Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. Am J Physiol Heart Circ Physiol 291 (2006) H687-H693
35. Yue T.L., Bao W., Gu J.L., et al. Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 54 (2005) 554-562
36. Taniguchi Y., Ooie T., Takahashi N., et al. Pioglitazone but not glibenclamide improves cardiac expression of heat shock protein 72 and tolerance against ischemia/reperfusion injury in the heredity insulin-resistant rat. Diabetes 55 (2006) 2371-2378
37. Xu Y., Gen M., Lu L., et al. PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol 288 (2005) H1314-H1323
38. Frustaci A., Kajstura J., Chimenti C., et al. Myocardial cell death in human diabetes. Circ Res 87 (2000) 1123-1132
39. Szabo C., Zanchi A., Komjati K., et al. Poly(ADP-ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation 106 (2002) 2680-2686
40. Ceriello A., Falleti E., Motz E., et al. Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res 30 (1998) 146-149
41. Upritchard J.E., Sutherland W.H., and Mann J.I. Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care 23 (2000) 733-738
42. Mohanty P., Aljada A., Ghanim H., et al. Rosiglitazone improves vascular reactivity, inhibits reactive oxygen species (ROS) generation, reduces p47phox subunit expression in mononuclear cells (MNC) and reduces C reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1): evidence of a potent anti-inflammatory effect. Diabetes 50 (2001) A68